Low Molecular Weight Heparin (LMWHs) is derived from UFH (Unfractionated heparin) by such processes as chemical degradation, enzymatic depolymerisation and gamma-radiation cleavage.
Natural heparin consists of molecular chains of varying lengths, or molecular weights. Chains of varying molecular weights, from 5000 to over 40,000 Daltons, make up polydisperse pharmaceutical-grade heparin. LMWHs, in contrast, consist of only short chains of polysaccharide. LMWHs are defined as heparin salts having an average molecular weight of less than 8000 Da and for which at least 60% of all chains have a molecular weight less than 8000 Da.
In 2016, in term of volume, the global Low molecular weight heparin market is led by china, capturing about 49.57% of global low molecular weight heparin production. In term of revenue, USA is the second’s largest market with the share of 30.49%.
At present, the major manufacturers of Low Molecular Weight Heparin are Aspen, Sanofi-aventis, Pfizer, Opocrin, CSBIO, Dongying Tiandong Pharmaceutical, Changzhou Qianhong Bio-pharma, Techdow, Yantai Dongcheng Pharmaceutical Group, etc. Aspen, Sanofi-aventis and Pfizer are industry-leading manufacturers of top-quality Low Molecular Weight Heparins.
China is a big low molecular weight heparin production country, especially Heparin API, but it is not strong country. According to our research and analysis, manufacturers from United States and Europe are the major leaders in the international market of low molecular weight heparin. Manufacturers from China are immature in technology. There is large space in the China market, as well as big gap between international brands and local brands on price.
In application, low molecular weight heparin downstream is wide and recently low molecular weight heparin has acquired increasing significance in various fields of treatment of venous thromboembolism, complications of pregnancy, cardioversion of atrial fibrillation/flutter and others.
Globally, the low molecular weight heparin market is mainly driven by growing demand for treatment of venous thromboembolism which accounts for nearly 65.24% of total downstream consumption of low molecular weight heparin in global.
Global Low Molecular Weight Heparin market size will increase to 410 Million US$ by 2025, from 270 Million US$ in 2018, at a CAGR of 5.4% during the forecast period. In this study, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Low Molecular Weight Heparin.
This report researches the worldwide Low Molecular Weight Heparin market size (value, capacity, production and consumption) in key regions like United States, Europe, Asia Pacific (China, Japan) and other regions.
This study categorizes the global Low Molecular Weight Heparin breakdown data by manufacturers, region, type and application, also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
The following manufacturers are covered in this report:
Dongying Tiandong Pharmaceutical
Changzhou Qianhong Bio-pharma
Yantai Dongcheng Pharmaceutical Group
Low Molecular Weight Heparin Breakdown Data by Type
Low Molecular Weight Heparin Breakdown Data by Application
Treatment of Venous Thromboembolism
Complications of Pregnancy
Cardioversion of Atrial Fibrillation/Flutter
Low Molecular Weight Heparin Production Breakdown Data by Region
Low Molecular Weight Heparin Consumption Breakdown Data by Region
Rest of Europe
Central & South America
Rest of South America
Middle East & Africa
Rest of Middle East & Africa
The study objectives are:
To analyze and research the global Low Molecular Weight Heparin capacity, production, value, consumption, status and forecast;
To focus on the key Low Molecular Weight Heparin manufacturers and study the capacity, production, value, market share and development plans in next few years.
To focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.
To define, describe and forecast the market by type, application and region.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends and factors driving or inhibiting the market growth.
To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
To strategically analyze each submarket with respect to individual growth trend and their contribution to the market.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of Low Molecular Weight Heparin :
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.